X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia
Retrieved on:
Monday, December 12, 2022
Security (finance), Fatigue, WHIM, Primary immunodeficiency, ASH, Disease, Neutrophil, Neutropenia, Pediatrics, Medication, Research, Blood, COVID-19, Diagnosis, Clinical trial, G-CSF, Trial of the century, Prevalence, FDA, Safety, Bone marrow, Birth, Society, HCPS, Therapy, Wart, Assistant, Quality of life, Hospital, Medicine, University, WHIM syndrome, Immune system, ANC, Patient, Knowledge Organization (journal), Cell, CXCR4, Degenerative disease, Cyclic neutropenia, Calendar, Risk, Pharmaceutical industry, Health insurance, Myelokathexis, Infection, Hypogammaglobulinemia
BOSTON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today provided a summary of its chronic neutropenia-related presentations at this year’s annual meeting of the American Society of Hematology (ASH), taking place December 10-13, 2022 in New Orleans.
Key Points:
- Data analyses continue to show that a single dose of oral mavorixafor effected meaningful increases in ANC across all participants, regardless of disease etiology or use of G-CSF.
- The Phase 1b clinical trial has now been amended and a Phase 2 trial ( NCT04154488 ) is being initiated by X4 to assess the durability, safety, and tolerability of the chronic use of once-daily, oral mavorixafor in a larger chronic neutropenia patient population.
- Participants were dosed with a single dose of 400 mg oral mavorixafor to assess the magnitude of treatment response.
- X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.